Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending March 2015. The document serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, in accordance with DTR 3.1.4 R(1)(a) and (c).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to a specific transaction notification and does not contain financial performance data.
Material Changes
The filing reports an increase in the notional allocation of GSK American Depositary Shares (ADSs) on February 27, 2015. This increase resulted from the revaluation of the cash element of the notional investment held within the GSK 401K plan. The transaction occurred at a price of $47.42 per ADS.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items beyond the specific transaction details noted above.
Important Facts for Investors
- Transaction Date: February 27, 2015 (notified March 2, 2015).
- Transaction Price: $47.42 per ADS.
- Director Activity: Dr M M Slaoui received a notional allocation increase of 19 ADSs.
- Connected Person Activity: Dr K Slaoui (connected person of Dr M M Slaoui) received a notional allocation increase of 4 ADSs.
- Source of Change: Revaluation of the cash element within the GSK 401K plan.